XML 80 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Schedule of Disaggregated Revenue by Product And Services
The following table provides information about disaggregated revenue by product and services:
 
    
Three Months Ended

March 31,
  
    
2022
     
2021
  
Product sales and rentals, net
    $ 651      $ 840  
Processing and storage fees, net
      1,283        1,264  
License, royalty and other
      4,001        556  
  
 
 
     
 
 
  
Net revenue
    $ 5,935      $ 2,660  
  
 
 
     
 
 
  
The following table provides information about disaggregated revenue by product and services:
 
    
Year Ended December 31,
  
    
    2021    
     
    2020    
  
Product sales and rentals
    $ 3,801      $ 6,854  
Services
      5,522        5,556  
License, royalty and other
      12,012        1,868  
    
 
 
     
 
 
  
Net revenues
    $ 21,335      $ 14,278  
    
 
 
     
 
 
  
Schedule of Changes in Deferred Revenue from Contract Liabilities
The following table provides changes in deferred revenue from contract liabilities:
 
    
2022
     
2021
  
Balance at January 1
    $  4,067      $  12,449  
Deferral of revenue*
      1,649        1,042  
Recognition of unearned revenue*
      (1,610 )       (1,639 ) 
  
 
 
     
 
 
  
Balance at March 31,
    $  4,106      $ 11,852  
  
 
 
     
 
 
  
 
*
2022 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.
The following table provides changes in deferred revenue from contract liabilities:
 
    
2021
     
2020
  
Balance at January 1
    $ 12,449      $ 3,833  
Deferral of revenue*
      4,928        14,532  
Recognition of unearned revenue**
      (13,310 )       (5,916 ) 
    
 
 
     
 
 
  
Balance at December 31
    $ 4,067      $ 12,449  
    
 
 
     
 
 
  
 
*
2020 includes $9,505 received in advance of performing services under a license agreement (see Note 15). The remainder of the 2020 and all of the 2021 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.
**
During the third quarter of 2021, the Company terminated the license agreement with Sanuwave due to an uncured material breach (See Note 15). As a result, the Company recognized the remaining deferred revenue of $6,754 that was to be recognized on a straight-line basis over the
non-cancelable
term of the license agreement.